Mike Westby

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Patrick Dorr, Mike Westby, Susan Dobbs et al. · Antimicrobial Agents and Chemotherapy · 2005 · 1.1K citations · Full text

Standard Deviations, Immunology, Pharmacotherapy +19

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

Gerd Fätkenheuer, Mark Nelson, Adriano Lazzarin et al. · New England Journal of Medicine · 2008 · 359 citations

Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry

Mike Westby, Caroline Smith‐Burchnell, Julie Mori et al. · Journal of Virology · 2006 · 346 citations

Phenotypic Susceptibility Assays, Immunology, Ccr5 Antagonist +16

Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir

Mike Westby, Marilyn Lewis, Jeannette M. Whitcomb et al. · Journal of Virology · 2006 · 330 citations · Full text

Ccr5 Antagonist Maraviroc, Ccr5 Tropic, Human Retrovirus +11

The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques

N. J. Philpott, John Scopes, Mike Westby et al. · Blood · 1996 · 329 citations · Full text